Facebook Linkedin RSS Twitter Youtube
Home 2023

CRISPR Therapeutics

2023 Year in Review: Business Developments
Industry News

2023 Year in Review: Business Developments

The First CRISPR Drug: Vertex Pharmaceuticals’ Casgevy Wins U.K. Approval for Sickle Cell Disease
Genome Editing

The First CRISPR Drug: Vertex Pharmaceuticals’ Casgevy Wins U.K. Approval for Sickle Cell Disease

Gene Therapy Briefs: Activist Investor Reported to Take $1B Stake in BioMarin
Drug Discovery

Gene Therapy Briefs: Activist Investor Reported to Take $1B Stake in BioMarin

CRISPR Prime Time? FDA Advisory Committee Evaluates Vertex Exa-Cel Therapy for Sickle Cell Disease
Genome Editing

CRISPR Prime Time? FDA Advisory Committee Evaluates Vertex Exa-Cel Therapy for Sickle Cell Disease

StockWatch: For Genome Editing, Inflection Points Crowd the Calendar
GEN Edge

StockWatch: For Genome Editing, Inflection Points Crowd the Calendar

Meeting on the Mesa: How to Bring Cell and Gene Therapies to Market
Bioprocessing

Meeting on the Mesa: How to Bring Cell and Gene Therapies to Market

StockWatch: Investors Shrug as FDA Weighs First Gene-Edited Therapy
Drug Discovery

StockWatch: Investors Shrug as FDA Weighs First Gene-Edited Therapy

Anticipating ASGCT with Terry Flotte
Genome Editing

Anticipating ASGCT with Terry Flotte

Prime-Edited Patient Blood Stem Cells Fully Engraft and Rescue Sickle Cell Mice
Genome Editing

Prime-Edited Patient Blood Stem Cells Fully Engraft and Rescue Sickle Cell Mice

Running Up That Hill: Nessan Bermingham on Close to the Edge
Close to the Edge

Running Up That Hill: Nessan Bermingham on Close to the Edge

123Page 2 of 3
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.